You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 312.8. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.2 mL||15.98 mL||31.97 mL|
|5 mM||0.64 mL||3.2 mL||6.39 mL|
|10 mM||0.32 mL||1.6 mL||3.2 mL|
|50 mM||0.06 mL||0.32 mL||0.64 mL|
References are publications that support the biological activity of the product.
Fox and Brotchie (1996) Normethylclozapine potentiates the action of quinpirole in the 6-hydroxyDA lesioned rat. Eur.J.Pharmacol. 301 27 PMID: 8773443
Kuoppamäki et al (1993) Clozapine and methylclozapine are potent 5-HT1C receptor antagonists. Eur.J.Pharmacol. 245 179 PMID: 8387927
Wong et al (1996) Effects of cloz. metabolites and chronic cloz. treatment on rat brain GABAA receptors. Eur.J.Pharmacol. 314 319 PMID: 8957253
If you know of a relevant reference for N-Desmethylclozapine, please let us know.
View Related Products by Product Action
Keywords: N-Desmethylclozapine, N-Desmethylclozapine supplier, 5-HT2C, antagonists, Serotonin, Receptors, Norclozapine, Normethylclozapine, 1007, Tocris Bioscience
3 Citations for N-Desmethylclozapine
Citations are publications that use Tocris products. Selected citations for N-Desmethylclozapine include:
Gregory et al (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285 7459 PMID: 20051519
Sur et al (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-MthD.-aspartate receptor activity. Proc Natl Acad Sci U S A 100 13674 PMID: 14595031
Magliaro and Saldanha (2009) Clozapine protects PC-12 cells from death due to oxidative stress induced by hydrogen peroxide via a cell-type specific mechanism involving inhibition of extracellular signal-regulated kinase phosphorylation. Brain Res 1283 14 PMID: 19501068
Do you know of a great paper that uses N-Desmethylclozapine from Tocris? Please let us know.
Reviews for N-Desmethylclozapine
There are currently no reviews for this product. Be the first to review N-Desmethylclozapine and earn rewards!
Have you used N-Desmethylclozapine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.